Ameloblastoma
(Redirected from Peripheral ameloblastoma)
A rare, benign tumor of the jaw
Ameloblastoma | |
---|---|
![]() | |
Synonyms | Adamantinoma of the jaw |
Pronounce | /əˌmiːloʊbləˈstoʊmə/ |
Field | Oral and maxillofacial surgery, Otorhinolaryngology, Oncology |
Symptoms | Painless swelling of the jaw, facial deformity, loosening of teeth |
Complications | Bone destruction, recurrence, rare malignant transformation |
Onset | Typically in adulthood (30–60 years) |
Duration | Chronic, slow-growing |
Types | Multicystic (solid), unicystic, peripheral, desmoplastic |
Causes | Neoplastic proliferation of odontogenic epithelium; may involve mutations in the BRAF gene |
Risks | No clear environmental risk factors; possibly genetic predisposition |
Diagnosis | Radiograph (e.g., panoramic X-ray), CT scan, MRI, biopsy |
Differential diagnosis | Odontogenic keratocyst, dentigerous cyst, fibrous dysplasia, osteosarcoma |
Prevention | None known |
Treatment | Surgical resection with wide margins; enucleation with curettage in some unicystic cases |
Medication | Targeted therapies (e.g., BRAF inhibitors) under research for recurrent/metastatic cases |
Prognosis | Good with complete surgical removal; high recurrence with inadequate resection |
Frequency | Rare; ~1% of all jaw tumors |
Deaths | Rare; malignant ameloblastoma may metastasize and be fatal |

Ameloblastoma is a rare, benign tumor that originates in the jawbone or sometimes in the soft tissues of the mouth. It is known for its aggressive local behavior and potential to cause significant bone destruction and facial deformity. Despite being benign, ameloblastomas can recur after treatment and rarely metastasize.
Epidemiology[edit | edit source]
Ameloblastomas account for about 1% of all oral tumors and approximately 11% of all odontogenic tumors. They are most commonly diagnosed in adults between the ages of 30 and 60, with no significant gender predilection. The majority of ameloblastomas occur in the mandible, particularly in the molar and ramus regions.
Pathophysiology[edit | edit source]
Ameloblastomas arise from the remnants of the dental lamina, the epithelial lining of odontogenic cysts, or from the basal cells of the oral mucosa. The tumor is characterized by the proliferation of ameloblast-like cells, which are similar to the cells that form the enamel of teeth. These cells form nests or islands within a fibrous stroma, leading to the characteristic histological appearance.
Clinical Presentation[edit | edit source]
Patients with ameloblastoma typically present with a painless swelling in the jaw, which may be noticed incidentally or due to facial asymmetry. As the tumor grows, it can cause tooth displacement, malocclusion, and paresthesia if it impinges on the inferior alveolar nerve. In advanced cases, the tumor can cause significant bone resorption and pathological fractures.
Diagnosis[edit | edit source]
The diagnosis of ameloblastoma is primarily based on imaging studies and histopathological examination. Panoramic radiographs and CT scans are commonly used to assess the extent of the tumor and its effects on the surrounding bone. The radiographic appearance is often described as a "soap bubble" or "honeycomb" pattern due to the multilocular radiolucencies. A definitive diagnosis is made through a biopsy and microscopic examination, which reveals the characteristic ameloblast-like cells.
Treatment[edit | edit source]
The treatment of ameloblastoma typically involves surgical resection. The extent of surgery depends on the size and location of the tumor. Options include enucleation, curettage, or more extensive resection with margins to prevent recurrence. In some cases, reconstructive surgery may be necessary to restore function and aesthetics. Radiotherapy and chemotherapy are generally not effective for ameloblastomas.
Prognosis[edit | edit source]
The prognosis for patients with ameloblastoma is generally good, with a high survival rate. However, the risk of recurrence is significant, particularly if the tumor is not completely excised. Long-term follow-up is essential to monitor for recurrence. Rarely, ameloblastomas can undergo malignant transformation into ameloblastic carcinoma, which has a poorer prognosis.
Related pages[edit | edit source]
External links[edit | edit source]
Classification | |
---|---|
External resources |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD